BioSpace News Archive

Drug Development

Pfizer Announces Positive Top-Line Results from Phase 2b/3 Trial of Ritlecitinib in Alopecia Areata

Pfizer Inc. announced positive top-line results from the Phase 2b/3 ALLEGRO trial evaluating oral once-daily ritlecitinib in patients with alopecia areata, an autoimmune disease driven by an immune attack on the hair follicles that causes hair loss on the scalp and can also affect the face and body.

August 4, 2021
·
9 min read
Pharm Country

NRx Pharmaceuticals Partners with MannKind Corporation to Develop ZYESAMI™ (aviptadil) Inhaler for Respiratory Conditions

NRx Pharmaceuticals announced it has signed an agreement with MannKind Corporation to develop a dry powder formulation of ZYESAMI™, a synthetic form of human Vasoactive Intestinal Peptide, produced by the body to help protect cells against inflammatory conditions.

August 4, 2021
·
6 min read
Business

AmerisourceBergen Reports Fiscal 2021 Third Quarter Results

AmerisourceBergen Corporation reported that in its fiscal year 2021 third quarter ended June 30, 2021, revenue increased 17.7 percent year-over-year to $53.4 billion.

August 4, 2021
·
46 min read
Biotech Beach

Zentalis Pharmaceuticals to Participate in the Wedbush PacGrow Healthcare Virtual Conference

Zentalis Pharmaceuticals, Inc. announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in a panel discussion at the Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 11, 2021 at 10:20 a.m. ET.

August 4, 2021
·
2 min read
BioMidwest

OrthoPediatrics Corp. and Mighty Oak Medical Extend Exclusive Partnership for FIREFLY Technology in Pediatric Orthopedics

OrthoPediatrics Corp., and Mighty Oak Medical, Inc. are pleased to announce the continuation of their navigation partnership, extending its current five-year deal another five years to August 2027.

August 4, 2021
·
3 min read
Business

Fulcrum Therapeutics to Host Second Quarter 2021 Financial Results Conference Call and Webcast on Tuesday, August 10, 2021 at 8:00 a.m. ET

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that its second quarter 2021 financial results will be released on Tuesday, August 10, 2021 before the U.S. financial markets open.

August 4, 2021
·
1 min read
Business

Editas Medicine Announces Second Quarter 2021 Results and Business Updates

Editas Medicine, Inc., a leading genome editing company, reported business highlights and financial results for the second quarter of 2021.

August 4, 2021
·
15 min read
Business

Orchard Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Business Updates

Orchard Therapeutics, a global gene therapy leader, reported financial results for the quarter ended June 30, 2021, as well as recent business updates and upcoming milestones.

August 4, 2021
·
16 min read
Pharm Country

Anavex Life Sciences to Participate in the BTIG Virtual Biotechnology Conference 2021

Anavex Life Sciences Corp. announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will participate in a fireside chat in the BTIG Virtual Biotechnology Conference 2021 on Tuesday, August 10, 2021 at 9:30 a.m. EDT.

August 4, 2021
·
3 min read
BioMidwest

Clearside Biomedical to Participate in Two Upcoming Investor Conferences in August 2021

Clearside Biomedical, Inc. announced that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer, and Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer, will participate in two upcoming investor conferences in August 2021:.

August 4, 2021
·
1 min read